News & Updates

Odevixibat improves pruritus, reduces bile acids in children with ALGS

13 Dec 2022 by

Treatment with odevixibat, a potent, selective IBAT* inhibitor, significantly improved pruritus and reduced serum bile acid levels in children with Alagille syndrome (ALGS), according to the ASSERT** trial presented at The Liver Meeting 2022.

Odevixibat improves pruritus, reduces bile acids in children with ALGS

13 Dec 2022

Resmetirom safe, effective in improving NASH fibrosis markers

12 Dec 2022 by

Treatment with the selective THR-β* agonist resmetirom for 52 weeks was well-tolerated and effective in reducing markers of NASH** fibrosis in a well-compensated Child-Pugh (CP)-A NASH population, a phase III trial has shown.

Resmetirom safe, effective in improving NASH fibrosis markers

12 Dec 2022

High-intensity focused ultrasound safe, effective for cirrhotic secondary hypersplenism

08 Dec 2022

High-intensity focused ultrasound (HIFU) appears to be a safe, effective, and minimally invasive treatment option for patients with cirrhotic secondary hypersplenism, a recent study has found.

High-intensity focused ultrasound safe, effective for cirrhotic secondary hypersplenism

08 Dec 2022

Midodrine a novel option for PICD prevention in ACLF

06 Dec 2022 by

Oral midodrine may be a good alternative to intravenous albumin for preventing paracentesis-induced circulatory dysfunction (PICD) in patients with acute-on-chronic liver failure (ACLF) undergoing modest-volume paracentesis for ascites, suggests a new study.

Midodrine a novel option for PICD prevention in ACLF

06 Dec 2022

Fatty liver more common in MAFLD than NAFLD

03 Dec 2022

Patients with metabolic dysfunction-associated fatty liver disease (MAFLD) see higher rates of fatty liver than those with nonalcoholic fatty liver disease (NAFLD), a recent study has found.

Fatty liver more common in MAFLD than NAFLD

03 Dec 2022

Yearly surveillance fails to detect cancer early in primary sclerosing cholangitis

01 Dec 2022

In unselected patients with primary sclerosing cholangitis (PSC), yearly surveillance with carbohydrate antigen (CA) 19-9 and magnetic resonance imaging including cholangiopancreatography (MRI/MRCP) does not seem to increase the chances of detecting cancer early, a new study has found.

Yearly surveillance fails to detect cancer early in primary sclerosing cholangitis

01 Dec 2022

MEFIB bests MAST, FAST for fibrosis detection in NAFLD

29 Nov 2022

Magnetic resonance elastography (MRE) plus FIB-4 (MEFIB) outperforms both magnetic resonance imaging [MRI]-aspartate aminotransferase (MAST) and FibroScan-AST (FAST) in detecting stage ≥2 fibrosis and at-risk nonalcoholic steatohepatitis (NASH), reveals a study.

MEFIB bests MAST, FAST for fibrosis detection in NAFLD

29 Nov 2022

LSM improves prediction of cholangitis outcomes

28 Nov 2022

Liver stiffness measurement (LSM) by vibration-controlled transient elastography (VCTE) is independently associated with primary biliary cholangitis (PBC) outcomes, a study has shown.

LSM improves prediction of cholangitis outcomes

28 Nov 2022

Married HCC patients have better overall survival

28 Nov 2022

Among hepatocellular carcinoma (HCC) patients, being married appears to have positive prognostic implications on overall survival (OS), a recent study has found.

Married HCC patients have better overall survival

28 Nov 2022

Bulevirtide safe, effective in HDV-induced cirrhosis with hypertension

27 Nov 2022

A recent study has demonstrated the safety and efficacy of bulevirtide (BLV) monotherapy for 48 weeks in difficult-to-treat patients with hepatitis delta virus (HDV)-related compensated cirrhosis and clinically significant portal hypertension (CSPH).

Bulevirtide safe, effective in HDV-induced cirrhosis with hypertension

27 Nov 2022

News & Updates

Filter by Specialty:

Specialty:

Odevixibat improves pruritus, reduces bile acids in children with ALGS

Odevixibat improves pruritus, reduces bile acids in children with ALGS

Resmetirom safe, effective in improving NASH fibrosis markers

Resmetirom safe, effective in improving NASH fibrosis markers

High-intensity focused ultrasound safe, effective for cirrhotic secondary hypersplenism

High-intensity focused ultrasound safe, effective for cirrhotic secondary hypersplenism

Midodrine a novel option for PICD prevention in ACLF

Midodrine a novel option for PICD prevention in ACLF

Fatty liver more common in MAFLD than NAFLD

Fatty liver more common in MAFLD than NAFLD

Yearly surveillance fails to detect cancer early in primary sclerosing cholangitis

Yearly surveillance fails to detect cancer early in primary sclerosing cholangitis

MEFIB bests MAST, FAST for fibrosis detection in NAFLD

MEFIB bests MAST, FAST for fibrosis detection in NAFLD

LSM improves prediction of cholangitis outcomes

LSM improves prediction of cholangitis outcomes

Married HCC patients have better overall survival

Married HCC patients have better overall survival

Bulevirtide safe, effective in HDV-induced cirrhosis with hypertension

Bulevirtide safe, effective in HDV-induced cirrhosis with hypertension